NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs
LOS ANGELES, CA - August 19, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and ...
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 6, 2025 (NEWMEDIAWIRE) - NRx ...
Hosted on MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NRx Pharmaceuticals (NASDAQ: NRXP) was ...
Hosted on MSN
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Austin, Texas, United States, October 6th ...
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback